Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
| Condition | Kidney Transplant Rejection, End Stage Renal Disease |
|---|---|
| Phase | Phase 1/2 |
| Sponsor | Sangamo Therapeutics |
| Status | Completed |
| Enrollment | 26 participants |
| Interventions | TX200-TR101 |
| Start date | Mar 17, 2021 |
| Completion date | Jul 11, 2024 |
| Results posted | Jul 2, 2026 |
Summary
The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients. TX200-TR101 is a product made from a kidney transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's body accept their donated kidney and prevent their immune system from rejecting it.
Short Term Safety and Tolerability of TX200-TR101 Infusion.
| Treatment With TX200-TR101 (DL1) | 1 Participants |
|---|---|
| Treatment With TX200-TR101 (DL2) | 0 Participants |
| Treatment With TX200-TR101 (DL3) | 0 Participants |
| Treatment With TX200-TR101 (DL4) | 1 Participants |
| Controls | 2 Participants |
| Donors | 0 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida